Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This book contains the art and science in current standards of surgical treatment of pancreatic ductal adenocarcinoma. It explains the clinical role of surgical resection during multimodal treatment in patients with pancreatic ductal adenocarcinoma, novel surgical techniques including extended pancreatectomy and minimally invasive surgery, risk of cancer in IPMN, and the clinical importance of liquid biopsy.

Medicine --- Surgery --- unresectable pancreatic ductal adenocarcinoma --- conversion surgery --- early recurrence --- pancreatic neoplasm/analysis --- pancreatic neoplasm/surgery --- tumor location --- survival --- clinical staging --- branch duct intraductal papillary mucinous neoplasm --- risk factor --- malignancy --- meta-analysis --- laparoscopic --- pancreaticoduodenectomy --- pancreatic cancer --- borderline resectable --- neoadjuvant treatment --- chemoradiotherapy --- prognostic nutritional index --- isolated local recurrence --- pancreatectomy --- pancreatic remnant --- recurrence --- redo surgery --- pancreatic exocrine insufficiency --- adjuvant chemotherapy --- biliary drainage --- prehabilitation --- ERAS --- arterial resection --- total pancreatectomy --- neoadjuvant therapy --- pancreatic ductal adenocarcinoma --- surgical treatment --- technical advances --- pancreatic main duct dilatation --- intraductal papillary mucinous neoplasm --- high grade dysplasia --- invasive carcinoma --- pancreatic cystic neoplasm --- cell-free DNA --- mesopancreas --- superior mesenteric artery --- nerve and fibrous tissues --- lymph node dissection --- R0 resection --- n/a

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This Special Issue is dedicated to neuroendocrine neoplasms (NENs), a category of malignancy that demonstrates wide clinical heterogeneity, posing major challenges in diagnosis and management. There have been significant advances in the field of NEN genomics, pathology, imaging, and treatment over the past five years. NENs are examples of rare tumours (although their incidence and prevalence are increasing) where international collaborative efforts have allowed the generation of high-level evidence to guide optimal patient-centred care. This issue presents both reviews and original papers to provide comprehensive state-of-the-art understanding of this fascinating disease.

Medicine --- small bowel neuroendocrine tumours --- pancreatic neuroendocrine tumours --- liver metastases --- midgut --- meta-analysis --- neuroendocrine tumors --- carcinoid heart disease --- carcinoid syndrome --- somatostatin analogues --- metastases --- multidisciplinary --- management --- outcome --- grading --- staging --- neuroendocrine neoplasms --- chemotherapy --- temozolomide --- metronomic treatment --- second-line --- NOTCH --- cancer-driven genes --- mutational mechanism --- germline mutations --- small cell lung carcinoma --- pancreatic NET --- small bowel NET --- medullary thyroid carcinoma --- malignant castration-resistant prostatic cells --- quality performance indicators --- QPIs --- cancer care --- neuroendocrine tumour --- NETs --- modified Delphi --- CommNETs --- pancreatic neuroendocrine neoplasms --- neuroendocrine tumor --- long-term functional outcomes --- pancreatectomy --- diabetes mellitus --- pancreatic exocrine insufficiency --- body mass index --- parenchyma-sparing surgery --- neuroendocrine tumours --- curative surgery --- resection --- follow-up --- guidelines --- relapse --- recurrence --- risk factor --- mixed non-neuroendocrine neuroendocrine neoplasms --- MiNENs --- mixed adeno-neuroendocrine carcinoma --- MANEC --- 2017 WHO classification --- 2019 WHO classification

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This Special Issue is dedicated to neuroendocrine neoplasms (NENs), a category of malignancy that demonstrates wide clinical heterogeneity, posing major challenges in diagnosis and management. There have been significant advances in the field of NEN genomics, pathology, imaging, and treatment over the past five years. NENs are examples of rare tumours (although their incidence and prevalence are increasing) where international collaborative efforts have allowed the generation of high-level evidence to guide optimal patient-centred care. This issue presents both reviews and original papers to provide comprehensive state-of-the-art understanding of this fascinating disease.

small bowel neuroendocrine tumours --- pancreatic neuroendocrine tumours --- liver metastases --- midgut --- meta-analysis --- neuroendocrine tumors --- carcinoid heart disease --- carcinoid syndrome --- somatostatin analogues --- metastases --- multidisciplinary --- management --- outcome --- grading --- staging --- neuroendocrine neoplasms --- chemotherapy --- temozolomide --- metronomic treatment --- second-line --- NOTCH --- cancer-driven genes --- mutational mechanism --- germline mutations --- small cell lung carcinoma --- pancreatic NET --- small bowel NET --- medullary thyroid carcinoma --- malignant castration-resistant prostatic cells --- quality performance indicators --- QPIs --- cancer care --- neuroendocrine tumour --- NETs --- modified Delphi --- CommNETs --- pancreatic neuroendocrine neoplasms --- neuroendocrine tumor --- long-term functional outcomes --- pancreatectomy --- diabetes mellitus --- pancreatic exocrine insufficiency --- body mass index --- parenchyma-sparing surgery --- neuroendocrine tumours --- curative surgery --- resection --- follow-up --- guidelines --- relapse --- recurrence --- risk factor --- mixed non-neuroendocrine neuroendocrine neoplasms --- MiNENs --- mixed adeno-neuroendocrine carcinoma --- MANEC --- 2017 WHO classification --- 2019 WHO classification